Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics
Author:
- 1 December 2018
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 192, 1-19
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (DK103616)
- Dr. Ralph and Marian Falk Medical Research Trust
This publication has 242 references indexed in Scilit:
- 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemiaBioorganic & Medicinal Chemistry Letters, 2011
- Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogsEuropean Journal of Pharmaceutical Sciences, 2010
- Epoxyeicosatrienoic acids and endothelium-dependent responsesPflügers Archiv - European Journal of Physiology, 2010
- Vascular Pharmacology of Epoxyeicosatrienoic Acids2010
- Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolaseCell Biology and Toxicology, 2008
- Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injuryProstaglandins & Other Lipid Mediators, 2007
- Fish Intake, Contaminants, and Human HealthJAMA, 2006
- The 5-substituted piperazine as a novel secondary pharmacophore greatly improving the physical properties of urea-based inhibitors of soluble epoxide hydrolaseBioorganic & Medicinal Chemistry, 2006
- Peptidyl-urea based inhibitors of soluble epoxide hydrolasesBioorganic & Medicinal Chemistry Letters, 2006
- Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolaseBioorganic & Medicinal Chemistry Letters, 2006